Ichnos Glenmark Innovation, Inc. (IGI), a subsidiary of Glenmark Pharmaceuticals Limited, has announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for its innovative cancer treatment, ISB 2301. This first-in-class multispecific immune cell activator is designed to target solid tumours by engaging both T cells and natural killer (NK) cells, marking a significant advancement in oncology therapeutics.
ISB 2301 is engineered to address the complexity and immune-suppressive nature of solid tumours by targeting three tumour-associated antigens. The molecule combines five binding specificities, enhancing tumour-cell recognition and immune activity. This strategic approach aims to overcome biological heterogeneity, a common challenge in cancer treatment. The submission of the IND represents a pivotal step in IGI’s development pipeline, with plans to initiate a Phase 1 clinical trial in 2027 to evaluate the safety and efficacy of ISB 2301 in patients with solid tumours.
Dr. Lida Pacaud, President and CEO of IGI, highlighted the significance of this development, stating, “The IND submission for ISB 2301 is a crucial milestone in advancing our multispecific oncology pipeline into clinical development. Our preclinical results have demonstrated a compelling anti-cancer profile for ISB 2301, which we believe is highly differentiated from current approaches.” The candidate was developed using IGI’s proprietary BEAT® Multispecific Platform, which has shown promising results in preclinical studies, including favourable pharmacokinetic and tolerability profiles in non-human primates.
Market analysts view this development as a promising step for Glenmark Pharmaceuticals in the competitive oncology sector. The innovative approach of ISB 2301, coupled with the robust preclinical data, positions Glenmark to potentially offer a novel treatment option for patients with advanced solid tumours. As the company progresses towards clinical trials, stakeholders will be closely monitoring the outcomes, which could significantly impact the company’s standing in the global biotechnology market.






